The Prediction of Hemorrhage Transformation by Cerebral Autoregulation in AIS Patient After Endovascular Thrombectomy
Launched by XUANWU HOSPITAL, BEIJING · Apr 8, 2024
Trial Information
Current as of July 05, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Part of the data from March 2022 to March 2022 was obtained, but it was still need more data and need a one-year follow-up of the data. Therefore, this is a 4 years prospective cohort study.
The objectives of the study were as follows: This observational study was designed for observe the cerebral hemodynamics and dynamic cerebral autoregulation (dCA) after endovascular thrombectomy (EVT) in acute ischemic stroke (AIS) patients. And analysis the relationship between the dCA damage degree and hemorrhage transformation (HT) and clinical outcomes. To explore the predictors of HT and adverse c...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • (i) age ≥18 years; (ii) complete recanalization of the affected MCA (thrombolysis in cerebral infarction grade 2b or 3); and (iii) sufficient temporal windows to obtain flow signals for the MCA.
- Exclusion Criteria:
- • (i) inability to perform dCA after EVT due to restlessness; (ii) re-occlusion of the culprit MCA after EVT; and (iii) other conditions such as low cerebral blood flow caused by severe heart disease.
About Xuanwu Hospital, Beijing
Xuanwu Hospital, located in Beijing, is a leading clinical research institution renowned for its commitment to advancing medical knowledge and improving patient care. Affiliated with Capital Medical University, the hospital specializes in neurology and rehabilitation, providing a robust framework for innovative clinical trials. With a multidisciplinary team of experienced researchers and healthcare professionals, Xuanwu Hospital focuses on conducting high-quality, ethically sound studies that aim to explore new treatment modalities and enhance therapeutic outcomes. Through its dedication to research excellence and patient-centered approaches, Xuanwu Hospital plays a pivotal role in the advancement of healthcare solutions both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Yingqi Xing, M.D.
Principal Investigator
Department of Vascular Ultrasonography, Xuanwu Hospital.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported